Derek N. J. Hart

Derek N. J. Hart

Auto-generated profile, based on publicly available information

Derek N. J. Hart

Dendritic Cell Research ANZAC Research Institute Sydney NSW Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2019 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
CBChristian E. Bryant
Christian E. Bryant
SSSarah Sutherland
Sarah Sutherland
BKBenjamin Kong
Benjamin Kong
MPMichael S. Papadimitrious
Michael S. Papadimitrious
PFPhillip D. Fromm
Phillip D. Fromm
DHDerek N.J. Hart
Derek N.J. Hart

16 February 2016 in Immunology & Cell Biology
Verified
Journal Article
Open access
CBChristian Bryant
Christian Bryant
PFPhillip D Fromm
Phillip D Fromm
FKFiona Kupresanin
Fiona Kupresanin
GCGeorgina Clark
Georgina Clark
KLKenneth Lee
Kenneth Lee
DHDerek Nj Hart
Derek Nj Hart
Human plasmacytoid dendritic cells (pDCs) were considered to be a phenotypically and functionally homogeneous cell population; however, recent analyses indicate potential heterogeneity. This is of major interest, given their importance in the induction of anti‐viral responses and their role in creating immunologically permissive environments for human malignancies. For this reason, we investigated the possible presence of human pDC subsets in blood and bone marrow, using unbiased cell phenotype clustering and functional studies. This defined two major functionally distinct human pDC subsets, distinguished by differential expression of CD2. The CD2hi and CD2lo pDCs represent discontinuous subsets, each with hallmark pDC functionality, including interferon‐alpha production. The rarer CD2hi pDC subset demonstrated a significant survival advantage over CD2lo pDC during stress and upon exposure to glucocorticoids (GCs), which was associated with higher expression of the anti‐apoptotic molecule BCL2. The differential sensitivity of these two human pDC subsets to GCs is demonstrated in vivo by a relative increase in CD2hi pDC in multiple myeloma patients treated with GCs. Hence, the selective apoptosis of CD2lo pDC during stress represents a novel mechanism for the control of innate responses.

15 December 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
XJxinsheng Ju
xinsheng Ju
PSPablo A Silveira
Pablo A Silveira
WHWei-Hsun Hsu
Wei-Hsun Hsu
ZEZehra Elgundi
Zehra Elgundi
RARenz Alingcastre
Renz Alingcastre
DHDerek N. J. Hart
Derek N. J. Hart
CD83 is a member of the Ig gene superfamily, first identified in activated lymphocytes. Since then, CD83 has become an important marker for defining activated human dendritic cells (DC). Several potential CD83 mRNA isoforms have been described, including a soluble form detected in human serum, which may have an immunosuppressive function. To further understand the biology of CD83, we examined its expression in different human immune cell types before and after activation using a panel of mouse and human anti-human CD83 mAb. The mouse anti-human CD83 mAbs, HB15a and HB15e, and the human anti-human CD83 mAb, 3C12C, were selected to examine cytoplasmic and surface CD83 expression, based on their different binding characteristics. Glycosylation of CD83, the CD83 mRNA isoforms, and soluble CD83 released differed among blood DC, monocytes, and monocyte-derived DC, and other immune cell types. A small T cell population expressing surface CD83 was identified upon T cell stimulation and during allogeneic MLR. This subpopulation appeared specifically during viral Ag challenge. We did not observe human CD83 on unstimulated human natural regulatory T cells (Treg), in contrast to reports describing expression of CD83 on mouse Treg. CD83 expression was increased on CD4+, CD8+ T, and Treg cells in association with clinical acute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients. The differential expression and function of CD83 on human immune cells reveal potential new roles for this molecule as a target of therapeutic manipulation in transplantation, inflammation, and autoimmune diseases.

1 August 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
TLTsun Ho Lo
Tsun Ho Lo
PSPablo A Silveira
Pablo A Silveira
PFPhillip D. Fromm
Phillip D. Fromm
NVNirupama D Verma
Nirupama D Verma
PVPhi A Vu
Phi A Vu
DHDerek N. J. Hart
Derek N. J. Hart
C-type lectin receptors play important roles in immune cell interactions with the environment. We described CD302 as the simplest, single domain, type I C-type lectin receptor and showed it was expressed mainly on the myeloid phagocytes in human blood. CD302 colocalized with podosomes and lamellopodia structures, so we hypothesized that it played a role in cell adhesion or migration. In this study, we used mouse models to obtain further insights into CD302 expression and its potential immunological function. Mouse CD302 transcripts were, as in humans, highest in the liver, followed by lungs, lymph nodes (LN), spleen, and bone marrow. In liver, CD302 was expressed by hepatocytes, liver sinusoidal endothelial cells, and Kupffer cells. A detailed analysis of CD302 transcription in mouse immune cells revealed highest expression by myeloid cells, particularly macrophages, granulocytes, and myeloid dendritic cells (mDC). Interestingly, 2.5-fold more CD302 was found in migratory compared with resident mDC populations and higher CD302 expression in mouse M1 versus M2 macrophages was also noteworthy. CD302 knockout (CD302KO) mice were generated. Studies on the relevant immune cell populations revealed a decrease in the frequency and numbers of migratory mDC within CD302KO LN compared with wild-type LN. In vitro studies showed CD302KO and wild-type DC had an equivalent capacity to undergo maturation, prime T cells, uptake Ags, and migrate toward the CCL19/CCL21 chemokines. Nevertheless, CD302KO migratory DC exhibited reduced in vivo migration into LN, confirming a functional role for CD302 in mDC migration.

25 January 2018 in OncoImmunology
Verified
Journal Article
Closed access
JHJennifer L. Hsu
Jennifer L. Hsu
CBChristian E. Bryant
Christian E. Bryant
MPMichael S. Papadimitrious
Michael S. Papadimitrious
BKBenjamin Kong
Benjamin Kong
RGRobin E. Gasiorowski
Robin E. Gasiorowski
DHDerek Nj Hart
Derek Nj Hart
Only modest advances in AML therapy have occurred in the past decade and relapse due to residual disease remains the major challenge. The potential of the immune system to address this is evident in the success of allogeneic transplantation, however this leads to considerable morbidity. Dendritic cell (DC) vaccination can generate leukemia-specific autologous immunity with little toxicity. Promising results have been achieved with vaccines developed in vitro from purified monocytes (Mo-DC). We now demonstrate that blood DC (BDC) have superior function to Mo-DC. Whilst BDC are reduced at diagnosis in AML, they recover following chemotherapy and allogeneic transplantation, can be purified using CMRF-56 antibody technology, and can stimulate functional T cell responses. While most AML patients in remission had a relatively normal T cell landscape, those who had received fludarabine as salvage therapy have persistent T cell abnormalities including reduced number, altered subset distribution, failure to expand, and increased activation-induced cell death. Furthermore, PD-1 and TIM-3 are increased on CD4T cells in AML patients in remission and their blockade enhances the expansion of leukemia-specific T cells. This confirms the feasibility of a BDC vaccine to consolidate remission in AML and suggests it should be tested in conjunction with checkpoint blockade.

1 October 2007 in Stem Cells and Development
Verified
Journal Article
Closed access
SFS.A.W. Fadilah
S.A.W. Fadilah
SVS. Vuckovic
S. Vuckovic
DKD. Khalil
D. Khalil
DHD.N.J. Hart
D.N.J. Hart
Methods that allow expansion of myeloid dendritic cells (MDCs) from CD34(+) cells are potentially important for boosting anti-leukemic responses after cord blood (CB) hematopoietic stem cell transplantation (HSCT). We showed that the combination of early-acting cytokines FLT3-ligand (FL), stem cell factor (SCF), interleukin (IL)-3, and IL-6 supported the generation of CD11c(+)CD16() CD1a()/c() MDCs from CB CD34(+) cells or CB myeloid precursors. Early-acting cytokine-derived MDCs were maintained within the myeloid CD33(+)CD14()CD15() precursors with a mean of 4 x 10(6) cells generated from 1-4 x 10(4) CB CD34(+) cells or myeloid precursors after 2 weeks. After 8-12 days of culture the MDCs expressed higher levels of HLA-DR antigen but lower levels of CD40 and CD86 antigen, compared to adult blood MDCs. At this stage of differentiation, the early-acting cytokine-derived MDCs had acquired the ability to induce greater allogeneic T cell proliferation than monocytes or granulocytes derived from same culture. Early-acting cytokine-derived MDCs exposed to the cytokine cocktail (CC) comprising IL-1beta, IL-6, tumor necrosis factor (TNF)-alpha, and prostaglandin E (PGE)-2, upregulated the surface co-stimulatory molecules CD40 and CD86 and enhanced allogeneic T cell proliferation, as is characteristic of MDCs maturation. The reliable production of MDCs from CB CD34(+) cells provides a novel way to study their lineage commitment pathway(s) and also a potential means of enriching CB with MDCs to improve prospects for DC immunotherapy following CB HSCT.